Following metastatic placental site trophoblastic tumor with urine β- core fragment

Kirsi Rinne*, Shohreh Shahabi, Laurence Cole

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Objective. We document a case with metastatic placental site trophoblastic tumor in a 47-year-old postmenopausal women. Methods. β-core fragment was measured in urine using the Triton UGP kit. hCG was also measured using the Bayer Immuno-1hCG assay (at Memorial Sloan-Kettering Cancer Center). Results. Over 2 years the patient underwent two courses of chemotherapy and two debulking operations. During this time, hCG levels decreased from 227 to 4.1 mIU/ml, hCG levels were close to the limit of detection (<3 mIU/ml), indicating complete or near-complete regression of disease. At this point urine β-core fragment levels were determined. High levels were detected 7.9 fmol/ml, consistent with the continued existence of tumor (>1.9 fmol/ml). High-dose chemotherapy (CEM) was started with stem cell harvesting. In the following weeks hCG levels failed to identify the tumor (4.1 to <3 mIU/ml). In the first week (during therapy) β-core fragment levels increased (12 fmol/ml), and in the following weeks (after therapy) levels regressed to 1.2 fmol/ml. Conclusion. Urine β-core fragment may be a useful tumor maker when serum hCG levels are near to or below the limit of detection.

Original languageEnglish (US)
Pages (from-to)302-303
Number of pages2
JournalGynecologic Oncology
Issue number2
StatePublished - Jan 1 1999


  • Placental site trophoblastic tumor
  • Tumor marker
  • β-core fragment
  • β-HCG

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Following metastatic placental site trophoblastic tumor with urine β- core fragment'. Together they form a unique fingerprint.

Cite this